BPC-157
Also known as: Bepecin, Body Protection Compound-157, Body Protective Compound‑157, BPC 157, BPC157, PL 14736, Stable Gastric Pentadecapeptide BPC-157
Source BPC-157 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
BPC‑157 (Body Protection Compound‑157) is a synthetic, 15‑amino‑acid peptide originally isolated from human gastric juice. It is investigated primarily for its potential to accelerate wound healing and repair of musculoskeletal tissues such as tendons, ligaments, muscle and bone. The compound remains a research‑only agent; it has not received regulatory approval for medical use.
Mechanism of Action
Preclinical work indicates that BPC‑157 modulates several intracellular pathways linked to tissue regeneration. It activates PI3K/Akt, mTOR, MAPK, TGF‑β and AMPK signaling, enhances growth‑hormone‑receptor expression, and stimulates angiogenic factors and integrin‑mediated extracellular‑matrix remodeling. The peptide also appears to promote fibroblast activation, resolve platelet‑fibrin clots, and counteract vascular constriction, collectively supporting rapid tissue repair and anti‑thrombotic effects.
What the Research Shows
The literature on BPC‑157 is dominated by animal studies. In rodents, the peptide accelerates skin wound closure, deep‑burn healing, and repairs of tendon, ligament, muscle and bone injuries, often via enhanced angiogenesis and reduced inflammatory cytokines. A 2025 systematic review identified 35 preclinical studies showing functional and biomechanical improvements, and a single retrospective human case series (12 knee pain patients) reporting sustained relief in 7 participants after intra‑articular injection, though methodological limitations were noted. No controlled clinical trials have been published, and safety data in humans are absent despite an overall favorable preclinical toxicity profile.
Reported Benefits
Animal experiments consistently demonstrate that BPC‑157 speeds closure of cutaneous wounds, burns and gastrointestinal lesions, and improves healing of musculoskeletal lesions by increasing angiogenesis, collagen deposition and biomechanical strength. In the limited human evidence, a small case series suggested potential pain relief after intra‑articular administration for chronic knee discomfort. These benefits are supported by observed modulation of growth‑factor pathways and anti‑inflammatory effects in preclinical models.
Limitations of the Evidence
Evidence is confined largely to rodent models; human data consist of uncontrolled case reports with small sample sizes. No randomized or blinded clinical trials have evaluated efficacy, optimal dosing, or long‑term outcomes. Regulatory agencies have not approved BPC‑157, and its status in sport varies. Consequently, the translation of preclinical success to clinical practice remains uncertain.
Safety Considerations
Preclinical toxicity studies report no lethal dose (LD1 not reached) and no organ‑specific adverse effects, suggesting a wide safety margin. Human safety data are lacking; the single retrospective series did not report systematic adverse events. Potential risks stem from unregulated manufacturing, contamination, and unknown immunogenicity when used in people. Caution is advised until rigorous clinical safety assessments are completed.
How It Is Administered
BPC‑157 has been administered to animals via intramuscular, subcutaneous, intraperitoneal and oral routes. Human case reports described a single intra‑articular knee injection. Formulations are typically aqueous solutions for injection; oral dosing has been explored in animal studies but human oral bioavailability is not established.
Routes of Administration
Goals & Uses
- Anti‑inflammatory effectInflammationLow
- Muscle repair and recoveryMusculoskeletal RepairLow
- Angiogenesis promotionVascularLow
- Tendon and ligament healingMusculoskeletal RepairModerate
- Gastrointestinal ulcer repairGastrointestinalModerate
- Neuroprotection and Neural RepairNeurologyLow
- Accelerate soft‑tissue healingRegenerativeModerate
- Anti-inflammatory effectsInflammationLow
- Gastrointestinal healing and protectionGI CytoprotectionModerate
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- History of hormone-sensitive cancersOncologicalModerate
- Severe hepatic impairmentOrganLowLiver function concerns
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to BPC-157 or excipientsAllergyHigh
Adverse Effects
- Dizziness or lightheadednessNeurologicalUncommon
- Theoretical tumor promotionOncologicalUnknown
- Injection site reactionsLocalCommon
- Hormonal axis perturbationEndocrineUnknown
- Local injection site irritationLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
Drug Interactions
- Anticoagulants (e.g., warfarin)Moderate
- Dopaminergic agents (e.g., L-DOPA, dopamine agonists)Moderate
- VEGF-targeting therapies (e.g., bevacizumab)High
- Anticoagulants / antiplateletsModerate
- NSAIDsLowMay increase renal risk in susceptible patients
Population Constraints
- Pediatric patientsAgeAbsolute
- Elderly >75 yearsAgeRelative
- Patients with active cancerOncologicalRelative
- Pregnant or lactating womenReproductiveAbsolute
- Children <12 yearsAgeRelative
- Immunocompromised individualsImmunologicalRelative
Regulatory Status
- European UnionUnapprovedNo EMA marketing authorization; only for laboratory use.
- United StatesUnapprovedClassed as investigational research chemical; not FDA‑approved.
- United KingdomUnapprovedNot licensed by MHRA; restricted to research.
Not approved for human use in the US, EU, or UK; available only as a research chemical.
Evidence & Sources
- Journal ArticleModerateRahman OF, Lee SJ, Seeds WA2026-01-01T00:00:00.000000Z
- Journal ArticleModerateMayfield CK, et al.2026-01-01T00:00:00.000000Z
- Journal ArticleModerateSeiwerth S, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateJózwiak M, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateVasireddi N, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleModerateGwyer D, Wragg NM, Wilson SL2019-01-01T00:00:00.000000Z
Frequently Asked Questions
Is BPC‑157 an approved medication?
No. BPC‑157 is classified as a research peptide and has not received FDA or other major regulatory approval for any medical indication.
What conditions has BPC‑157 been studied for?
Preclinical studies focus on skin and gastrointestinal wound healing, and on musculoskeletal injuries such as tendon, ligament, muscle and bone repair. Human evidence is limited to a small case series for chronic knee pain.
Are there any known side effects?
Animal studies report no significant toxicity, but human safety data are absent. Risks may arise from impurities or contamination in unregulated products.
How is BPC‑157 typically given in research?
In laboratory settings it is delivered by injection (intramuscular, subcutaneous, intraperitoneal) or orally in animal models; a human case series used a single intra‑articular injection.
Can athletes use BPC‑157 legally?
The peptide was temporarily banned by WADA in 2022 and is not currently listed, but its use is not approved medically and may still be prohibited by individual sport governing bodies.
What is BPC-157?
BPC‑157 (Body Protection Compound‑157) is a synthetic, 15‑amino‑acid peptide originally isolated from human gastric juice. It is investigated primarily for its potential to accelerate wound healing and repair of musculoskeletal tissues such as tendons, ligaments, muscle and bone. The compound remains a research‑only agent; it has not received regulatory approval for medical use.
What is BPC-157 used for?
BPC-157 is educationally associated with: Anti‑inflammatory effect, Muscle repair and recovery, Angiogenesis promotion, Tendon and ligament healing, Gastrointestinal ulcer repair, Neuroprotection and Neural Repair, Accelerate soft‑tissue healing, Anti-inflammatory effects, Gastrointestinal healing and protection. Educational only — not medical advice.
How is BPC-157 administered?
Recorded routes of administration: Intramuscular, Intraperitoneal, Oral, Subcutaneous.
What are the potential side effects of BPC-157?
Reported adverse effects include: Dizziness or lightheadedness, Theoretical tumor promotion, Injection site reactions, Hormonal axis perturbation, Local injection site irritation, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid BPC-157?
Recorded contraindications: Active malignancy, History of hormone-sensitive cancers, Severe hepatic impairment, Pregnancy, Known hypersensitivity to BPC-157 or excipients. Consult a qualified clinician before use.